20110411
 Health & Wellness: Novartis Cancels Cancer Drug   By Greil, Anita, The Wall Street Journal,  Apr 12, 2011  Tasigna, however, may still be able to offset an expected drop of sales from Gleevec's main use as treatment of a certain type of blood cancer, for which it has won marketing approval in Europe and the U.S. In other news, Novartis's new analysis of its multiple sclerosis drug Gilenya showed the pill lowered the risk of the disease getting worse in patients with relapsing-remitting MS, regardless of treatment history.   
